SCHEMBL221782

SCHEMBL221782

CC(C)N1CCC(N(Cc2cccnc2)S(=O)(=O)CCNC(=O)c2ccc(Cl)s2)CC1

nearest known ligand 0.57

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
F10 P00742 4/20 0.57
CCR5 P51681 9/20 0.41
UBE2M P61081 3/20 0.40
DCUN1D1 Q96GG9 3/20 0.40
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.37
DYRK1A Q13627 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL219979 0.83 F10 (0.58) F10MAPK1
SCHEMBL219860 0.83 F10 (0.65) F10MAPK1
SCHEMBL221194 0.81 F10 (0.59) F10MAPK1
SCHEMBL220224 0.81 F10 (0.57) F10
SCHEMBL219872 0.81 F10 (0.63) F10MAPK1
SCHEMBL221251 0.81 F10 (0.63) F10MAPK1
SCHEMBL221417 0.81 F10 (0.63) F10MAPK1
SCHEMBL219743 0.81 F10 (0.63) F10CCR5MAPK1
SCHEMBL221616 0.81 F10 (0.60) F10MAPK1
SCHEMBL221193 0.81 F10 (0.69) F10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 US claimed
US-8088925-B2 low molecular weight factor Xa specific blood clotting inhibitors; less side effects; 5-Chloro-thiophene-2-carboxylic acid [2-(1-isopropyl-piperidin-4-ylsulfamoyl)-ethyl]-amide; thromboembolic diseases or restenosis; antithrombotic agents SANOFI-AVENTIS (FR) 2012-01-03 US disclosed